Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction

Yusuke Murata, Yuko Kamishioiri, Kenji Tanaka, Hiroko Sugimoto, Shoko Sakamoto, Daisuke Kobayashi, Kazunori Mine

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Severe sleepiness and excess sleep duration, "Hypersomnia", induced by paroxetine treatment are generally considered adverse drug reactions, however, our experience indicates that patients with depressive disorder who experience "Hypersomnia" during paroxetine treatment have good clinical response. The aim of this study was to determine if "Hypersomnia" during paroxetine treatment is a beneficial pharmacological effect or an adverse drug reaction, and to investigate the impact of genetic polymorphisms on individual differences in the occurrence of "Hypersomnia" induced by paroxetine. Methods: A consecutive series of 46 Japanese patients with depressive disorder were treated with paroxetine. Patients who complained of great drowsiness or who slept for more than 12-h per day over seven days were identified as having experienced "Hypersomnia". For the clinical improvement rates and genotype distribution of the circadian locomotor output cycles kaput (CLOCK), serotonin transporter and cytochrome P450 2D6 (CYP2D6), the group that showed "Hypersomnia" induced by paroxetine treatment and the group that did not show "Hypersomnia" were compared statistically. Results: Patients who experienced "Hypersomnia" (17.4%) showed a significantly higher response rate at two weeks than did patients who did not experience "Hypersomnia" (p=0.0127). No significant association between the occurrence of "Hypersomnia" and genetic polymorphisms was found. Limitations: We cannot exclude the risk of false positive errors due to the relatively small sample sizes. Conclusions: "Hypersomnia" during paroxetine treatment for depression is a beneficial pharmacological effect, not an adverse drug reaction.

Original languageEnglish
Pages (from-to)1209-1212
Number of pages4
JournalJournal of Affective Disorders
Volume150
Issue number3
DOIs
Publication statusPublished - Sep 25 2013

Fingerprint

Disorders of Excessive Somnolence
Paroxetine
Sleep
Pharmacology
Drug-Related Side Effects and Adverse Reactions
Therapeutics
Genetic Polymorphisms
Depressive Disorder
Cytochrome P-450 CYP2D6
Serotonin Plasma Membrane Transport Proteins
Sleep Stages
Individuality
Sample Size

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction. / Murata, Yusuke; Kamishioiri, Yuko; Tanaka, Kenji; Sugimoto, Hiroko; Sakamoto, Shoko; Kobayashi, Daisuke; Mine, Kazunori.

In: Journal of Affective Disorders, Vol. 150, No. 3, 25.09.2013, p. 1209-1212.

Research output: Contribution to journalArticle

Murata, Yusuke ; Kamishioiri, Yuko ; Tanaka, Kenji ; Sugimoto, Hiroko ; Sakamoto, Shoko ; Kobayashi, Daisuke ; Mine, Kazunori. / Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction. In: Journal of Affective Disorders. 2013 ; Vol. 150, No. 3. pp. 1209-1212.
@article{4338befb5a9748d9a452cfc06e9f2e0e,
title = "Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction",
abstract = "Background: Severe sleepiness and excess sleep duration, {"}Hypersomnia{"}, induced by paroxetine treatment are generally considered adverse drug reactions, however, our experience indicates that patients with depressive disorder who experience {"}Hypersomnia{"} during paroxetine treatment have good clinical response. The aim of this study was to determine if {"}Hypersomnia{"} during paroxetine treatment is a beneficial pharmacological effect or an adverse drug reaction, and to investigate the impact of genetic polymorphisms on individual differences in the occurrence of {"}Hypersomnia{"} induced by paroxetine. Methods: A consecutive series of 46 Japanese patients with depressive disorder were treated with paroxetine. Patients who complained of great drowsiness or who slept for more than 12-h per day over seven days were identified as having experienced {"}Hypersomnia{"}. For the clinical improvement rates and genotype distribution of the circadian locomotor output cycles kaput (CLOCK), serotonin transporter and cytochrome P450 2D6 (CYP2D6), the group that showed {"}Hypersomnia{"} induced by paroxetine treatment and the group that did not show {"}Hypersomnia{"} were compared statistically. Results: Patients who experienced {"}Hypersomnia{"} (17.4{\%}) showed a significantly higher response rate at two weeks than did patients who did not experience {"}Hypersomnia{"} (p=0.0127). No significant association between the occurrence of {"}Hypersomnia{"} and genetic polymorphisms was found. Limitations: We cannot exclude the risk of false positive errors due to the relatively small sample sizes. Conclusions: {"}Hypersomnia{"} during paroxetine treatment for depression is a beneficial pharmacological effect, not an adverse drug reaction.",
author = "Yusuke Murata and Yuko Kamishioiri and Kenji Tanaka and Hiroko Sugimoto and Shoko Sakamoto and Daisuke Kobayashi and Kazunori Mine",
year = "2013",
month = "9",
day = "25",
doi = "10.1016/j.jad.2013.05.040",
language = "English",
volume = "150",
pages = "1209--1212",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction

AU - Murata, Yusuke

AU - Kamishioiri, Yuko

AU - Tanaka, Kenji

AU - Sugimoto, Hiroko

AU - Sakamoto, Shoko

AU - Kobayashi, Daisuke

AU - Mine, Kazunori

PY - 2013/9/25

Y1 - 2013/9/25

N2 - Background: Severe sleepiness and excess sleep duration, "Hypersomnia", induced by paroxetine treatment are generally considered adverse drug reactions, however, our experience indicates that patients with depressive disorder who experience "Hypersomnia" during paroxetine treatment have good clinical response. The aim of this study was to determine if "Hypersomnia" during paroxetine treatment is a beneficial pharmacological effect or an adverse drug reaction, and to investigate the impact of genetic polymorphisms on individual differences in the occurrence of "Hypersomnia" induced by paroxetine. Methods: A consecutive series of 46 Japanese patients with depressive disorder were treated with paroxetine. Patients who complained of great drowsiness or who slept for more than 12-h per day over seven days were identified as having experienced "Hypersomnia". For the clinical improvement rates and genotype distribution of the circadian locomotor output cycles kaput (CLOCK), serotonin transporter and cytochrome P450 2D6 (CYP2D6), the group that showed "Hypersomnia" induced by paroxetine treatment and the group that did not show "Hypersomnia" were compared statistically. Results: Patients who experienced "Hypersomnia" (17.4%) showed a significantly higher response rate at two weeks than did patients who did not experience "Hypersomnia" (p=0.0127). No significant association between the occurrence of "Hypersomnia" and genetic polymorphisms was found. Limitations: We cannot exclude the risk of false positive errors due to the relatively small sample sizes. Conclusions: "Hypersomnia" during paroxetine treatment for depression is a beneficial pharmacological effect, not an adverse drug reaction.

AB - Background: Severe sleepiness and excess sleep duration, "Hypersomnia", induced by paroxetine treatment are generally considered adverse drug reactions, however, our experience indicates that patients with depressive disorder who experience "Hypersomnia" during paroxetine treatment have good clinical response. The aim of this study was to determine if "Hypersomnia" during paroxetine treatment is a beneficial pharmacological effect or an adverse drug reaction, and to investigate the impact of genetic polymorphisms on individual differences in the occurrence of "Hypersomnia" induced by paroxetine. Methods: A consecutive series of 46 Japanese patients with depressive disorder were treated with paroxetine. Patients who complained of great drowsiness or who slept for more than 12-h per day over seven days were identified as having experienced "Hypersomnia". For the clinical improvement rates and genotype distribution of the circadian locomotor output cycles kaput (CLOCK), serotonin transporter and cytochrome P450 2D6 (CYP2D6), the group that showed "Hypersomnia" induced by paroxetine treatment and the group that did not show "Hypersomnia" were compared statistically. Results: Patients who experienced "Hypersomnia" (17.4%) showed a significantly higher response rate at two weeks than did patients who did not experience "Hypersomnia" (p=0.0127). No significant association between the occurrence of "Hypersomnia" and genetic polymorphisms was found. Limitations: We cannot exclude the risk of false positive errors due to the relatively small sample sizes. Conclusions: "Hypersomnia" during paroxetine treatment for depression is a beneficial pharmacological effect, not an adverse drug reaction.

UR - http://www.scopus.com/inward/record.url?scp=84888343709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888343709&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2013.05.040

DO - 10.1016/j.jad.2013.05.040

M3 - Article

C2 - 23809402

AN - SCOPUS:84888343709

VL - 150

SP - 1209

EP - 1212

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 3

ER -